Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1978;58:273-279

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, B. H.
Right arrow Articles by Chatterjee, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, B. H.
Right arrow Articles by Chatterjee, K.

Circulation, Vol 58, 273-279, Copyright © 1978 by American Heart Association


ARTICLES

Beneficial effects of hydralazine in severe mitral regurgitation

BH Greenberg, BM Massie, BH Brundage, EH Botvinick, WW Parmley and K Chatterjee

The severity of mitral regurgitation is, in part, determined by aortic impedance to left ventricular outflow. Sodium nitroprusside acutely decreases regurgitant flow, but the importance of its dual vasodilating effects, the lowering of peripheral vascular resistance and increasing of venous capacitance, is unclear. We studied the hemodynamic response to intravenous hydralazine, which selectively acts on the arteriolar resistance bed, in 10 patients with severe mitral regurgitation. Hydralazine produced a 50% increase in forward stroke volume (22 +/- 2 to 33 +/- 3 ml/m2, P less than 0.001) and a 33% reduction in regurgitant stroke volume (40 +/- 6 to 27 +/- 6 ml/m2, P less than 0.001), with a resultant fall in pulmonary capillary wedge v wave and mean pressures. Unlike nitroprusside, it did not alter left ventricular end-diastolic volume or pressure. Oral hydralazine maintained this hemodynamic improvement for at least 48 hours and, in three patients, provided more sustained clinical improvement. We conclude that hydralazine, by virtue of its selective lowering of aortic impedance, reduces the amount of mitral regurgitation and thus may be a useful mode of interim or chronic therapy in selected patients.


This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
C. Sekuri, O. Utuk, O. Bayturan, A. Bilge, Z. Kurhan, and T. Tavli
Effect of losartan on exercise tolerance and echocardiographic parameters in patients with mitral regurgitation
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 107 - 111.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
L. B. Rosario, L. W. Stevenson, S. D. Solomon, R. T. Lee, and S. C. Reimold
The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size
J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1819 - 1824.
[Abstract] [Full Text] [PDF]


Home page
J Intensive Care MedHome page
M. H. Crawford
Acute Mitral Regurgitation
J Intensive Care Med, December 1, 1986; 1(6): 329 - 335.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
L. Gould, C. Gopalaswamy, F. Chandy, and O. Abdou
Noninvasive Assessment of Left Ventricular Wall Stress in Chronic Congestive Heart Failure Patients
Angiology, February 1, 1983; 34(2): 111 - 118.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
B. H. GREENBERG, R. SCHUTZ, G. L. GRUNKEMEIER, and H. GRISWOLD
Acute Effects of Alcohol in Patients with Congestive Heart Failure
Ann Intern Med, August 1, 1982; 97(2): 171 - 175.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
G. L. Pierpont and R. C. Talley
Pathophysiology of Valvar Heart Disease: The Dynamic Nature of Mitral Valve Regurgitation
Arch Intern Med, May 1, 1982; 142(5): 998 - 1001.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
L. Gould, V.R. Reddy, S. Patel, G.I. Gomes, and W. H. Becker
Noninvasive Assessment of Load Reduction in Chronic Congestive Heart Failure Patients
Angiology, August 1, 1981; 32(8): 552 - 560.
[PDF]


Home page
JAMAHome page
B. H. Greenberg and S. H. Rahimtoola
Vasodilator Therapy for Valvular Heart Disease
JAMA, July 17, 1981; 246(3): 269 - 272.
[Abstract] [PDF]


Home page
ANGIOLOGYHome page
L. Gould, C.V.R. Reddy, Bujung Zen, and B.K. Singh
Effect of Nitroglycerin Ointment on Hemodynamics in Patients With Mitral Insufficiency
Angiology, October 1, 1980; 31(10): 677 - 685.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
K. CHATTERJEE, T. A. PORTS, B. H. BRUNDAGE, B. MASSIE, A. N. HOLLY, and W. W. PARMLEY
Oral Hydralazine in Chronic Heart Failure: Sustained Beneficial Hemodynamic Effects
Ann Intern Med, May 1, 1980; 92(5): 600 - 604.
[Abstract] [PDF]